header logo en

How Can I Find a Clinical Trial for Kidney Cancer?

Taking part in a clinical trial can be a good choice but it is often hard to find a clinical trial that is right for you. Many patient organisations and websites maintain lists of clinical trials. The following tables list some of the many clinical trials available worldwide and focus primarily on immuno-oncology trials for kidney cancer patients. Please note: this is not an exhaustive list, so please check with your local patient organisation. Other trials may be available in your country. If you are aware of an open trial that should be listed here, please send us the trial information to: This email address is being protected from spambots. You need JavaScript enabled to view it.

For more clinical trials for kidney cancer please search the IKCC clinical trials database: IKCC clinical trials database

For more information about understanding and finding trials, click here.

 

Pre-surgery (neo adjuvant) trials (for patients before surgery to remove the kidney tumour)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
ADAPTeR   Nivolumab pre and post-OP  II           
 Open,
 recruiting
Royal Marsden click here
Pembrolizumab-031 Pembrolizumab (MK-3475)  I
 Open,
 recruiting 
Merck Sharp  
 & Dohme  Corp.
click here
PROSPER Nivolumab III  Open,  recruiting Dana Faber Cancer Institute click here

Adjuvant trials (for patients immediately after surgery)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
IMmotion010   Atezolizumab  III           
 Open,
 recruiting
Hoffmann-La Roche click here
Checkmate  914 Nivolumab + Ipilimumab   III  Open,  recruiting Bristol-Myers  Squibb click here
Keynote 564 Pembrolizumab  III  Open,  recruiting Merck Sharp & Dohme Corp. click here
PROSPER Nivolumab  III
 Open,
 recruiting
Dana Faber Cancer Institute  click here

First line treatment (for patients who have not yet had any systemic therapy for advanced kidney cancer)

 Trial name  Agents  Phase   Status  Sponsor  Further  information 
Checkmate 214   
Nivolumab+ipilimumab  
versus sunitinib
 III  Closed to  accrual Bristol-Myers Squibb click here
ADAPT
AGS-003 versus
sunitinib
 III  Ongoing,  not  recruiting Argos Therapeutics click here
Atezolizumab (MPDL3280 A) + bevacizumab versus
sunitinib
 III
 Ongoing,
 not 
 recruiting
Hoffmann-La Roche click here
Javelin Renal 101 Avelumab + axitinib  III
 Open,
 recruiting
Pfizer click here
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab  II 
 Ongoing,  not  recruiting
MD Anderson click here 
interferon alpha 2a
 I/II  Completed  Spanish Oncology Genito-Urinary Group
Novartis
click here
Pembrolizumab + bevacizumab
Pembrolizumab +
bevacizumab
 I/II
 Ongoing,  not  recruiting
Merck Sharp & Dohme Corp. click here
Atezolizumab +
interferon alpha 2b
 I  Open,  recruiting Hoffman-La Roche click here
Pembrolizumab + pazopanib
Pembrolizumab +
pazopanib
 I  Ongoing,  not  recruiting
Novartis, 
Merck Sharp
& Dohme Corp.
click here
Pembrolizumab + axitinb
Pembrolizumab +
axitinb
 I  Ongoing,  not  recruiting Pfizer click here
Javelin renal 100 Avelumab + axitinib  I  Open,  recruiting Pfizer click here
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab vs. Sunitinib  Lenvatinib, everolimus, pembrolizumab, sunitinib  III  Open,
 recruiting
Eisai Inc.
 
KEYNOTE-426 Pembolizumab + axitinib vs. sunitinib  III  Open,  recruiting Merck Sharp & Dohme Corp. click here

CheckMate 800 Nivolumab plus ipilimumab  II
 Open, 
 recruiting
Bristol-Myers Squibb click here

KEYNOTE-427 Pembrolizumab  II
 Open,
 recruiting
Merck Sharp & Dohme Corp. click here

FRACTION-RCC Nivolumab + ipilimumab vs. Nivolumab + BMS-986016  II  Open,  recruiting Bristol-Myers Squibb click here

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Pazopanib hydrochloride  III
 Ongoing,   not
 recruiting
National Cancer Institute (NCI) click here
Patient-friendly review will be available soon
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Atezolizumab + bevacizumab  II  Open,  recruiting Dana-Farber Cancer Institute click here
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma AGS-16C3F vs. axitinib  II  Open,  recruiting Agensys, Inc. click here
S1500 - Cabozantinib, Crizotinib, Volitinib, or Sunitinib in Treating Patients With Locally Advanced or Metastatic Papillary Kidney Cancer Cabozantinib, crizotinib, volitinib, sunitinib   II
 Open,
 recruiting
National Cancer Institute (NCI) click here
Savoir Savolitinib, sunitinib  III  Open,  recruiting AstraZeneca click here
Checkmate 920 Nivolumab, ipilimumab  IV
 Open,
 recruiting
Bristol-Myers Squibb click here
Checkmate 9ER Nivolumab, cabozantinib, ipilimumab, sunitinib  III
 Open,
 recruiting
Bristol-Myers Squibb click here

 

Second line treatment (for patients who have had only one prior systemic therapy)

 Trial name  Agents  Phase   Status  Sponsor  Further  information 
Checkmate 025 Nivolumab versus everolimus  III  Stopped,  results  published  at the  ECC  2015 Bristol-Myers Squibb click here
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab  II 
 Ongoing,
 not  recruiting
MD Anderson click here 
Pembrolizumab + interferon alpha 2b +
ipilimumab
 I/II  Open,    recruiting Merck Sharp & Dohme Corp. click here
Pazopanib +
interferon alpha 2a
 I/II  Completed  Spanish Oncology Genito-Urinary Group
Novartis
click here
Pembrolizumab + bevacizumab
Pembrolizumab +
bevacizumab
 I/II
 Ongoing,  not  recruiting
Merck Sharp & Dohme Corp. click here
Atezolizumab +
interferon alpha 2b
 I  Open,  recruiting Hoffman-La Roche click here
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab Cabozantinib + nivolumab + ipilimumab  I
 Open,
 recruiting
National Cancer Institute (NCI)/ Exelixis click here
X4P-001 in Patients With Advanced Renal Cell Carcinoma X4P-001 + axitinib  I/II  Open,  recruiting X4 Pharmaceuticals click here
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360)  Pembrolizumab (MK-3475) + Epacadostat (INCB024360)  I/II  Closed for  kidney  cancer  patients Incyte Corporation,
Merck Sharp & Dohme Corp.
click here
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours Lenvatinib + pembrolizumab   Ib/II  Open  recruiting Eisai Inc. click here
Checkmate 800 Nivolumab +ipilimumab  II  Open,  recruiting Bristol-Myers Squibb click here

FRACTION-RCC Nivolumab + ipilimumab vs. Nivolumab + BMS-986016  II  Open,
 recruiting
Bristol-Myers Squibb click here

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma AGS-16C3F vs. axitinib  II  Open,  recruiting Agensys, Inc. click here
S1500 - Cabozantinib, Crizotinib, Volitinib, or Sunitinib in Treating Patients With Locally Advanced or Metastatic Papillary Kidney Cancer Cabozantinib, crizotinib, volitinib, sunitinib   II
 Open,
 Recruiting
National Cancer Institute (NCI) click here
Savoir Savolitinib, sunitinib  III  Open,  recruiting AstraZeneca click here

Third line treatment (for patients who have had up to two prior systemic therapies)

 Trial name  Agents  Phase   Status  Sponsor  Further  information 
Checkmate 025 Nivolumab versus everolimus  III  Stopped,  results  published  at the  ECC  2015 Bristol-Myers Squibb click here
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab  II 
 Ongoing,
 not  recruiting
MD Anderson click here 
Pazopanib +
interferon alpha 2a
 I/II  Completed  Spanish Oncology Genito-Urinary Group
Novartis
click here
Pembrolizumab + bevacizumab
Pembrolizumab +
bevacizumab
 I/II
 Ongoing,  not  recruiting
Merck Sharp & Dohme Corp. click here
Atezolizumab +
interferon alpha 2b
 I  Open,  recruiting Hoffman-La Roche click here
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab Cabozantinib + nivolumab + ipilimumab  I
 Open,
 recruiting
National Cancer Institute (NCI)/ Exelixis click here
X4P-001 in Patients With Advanced Renal Cell Carcinoma X4P-001 + axitinib  I/II  Open,  recruiting X4 Pharmaceuticals click here
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360)  Pembrolizumab (MK-3475) + epacadostat (INCB024360)  I/II  Closed for  kidney  cancer  patients Incyte Corporation,
Merck Sharp & Dohme Corp.
click here
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours Lenvatinib + Pembrolizumab  Ib/II
 Open,
 recruiting
Eisai Inc. click here
Checkmate 800 Nivolumab + ipilimumab  II
 Open,
 recruiting
Bristol-Myers Squibb click here

Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Tivozanib Hydrochloride vs. sorafenib  III
 Ongoing,
 not
 recruiting
AVEO Pharmaceuticals, Inc. click here

FRACTION-RCC Nivolumab + ipilimumab vs. Nivolumab + BMS-986016  II  Open,
 recruiting
Bristol-Myers Squibb click here

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma AGS-16C3F vs. axitinib  II  Open,  recruiting Agensys, Inc. click here
Savoir Savolitinib, sunitinib  III  Open,  recruiting AstraZeneca click here

Others

Currently no other trials available.